Kinetic modeling of 3′-deoxy-3′-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice

Journal of Nuclear Medicine

Volumn 49, Issue 12, 2008, Pages 2057-2066

  Su, Jin Kim ^a   Jae, Sung Lee ^a   Ki, Chum Im ^b,c   Kim, Seog Young ^b,c   Park, Soo Ah ^b,c   Seung, Jin Lee ^b,c   Seung, Jun Oh ^b,c   Dong, Soo Lee ^a   Dae, Hyuk Moon ^b,c  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

3 deoxy 3 18F fluorothymidine ( 18F FLT); Arterial input function; Cellular proliferation; Kinetic modeling

Indexed keywords

3' FLUOROTHYMIDINE F 18; KI 67 ANTIGEN; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CARCINOMA; CELL PROLIFERATION; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATIONAL STUDY; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; KINETICS; LEWIS CARCINOMA; METABOLITE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR MODEL;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DIDEOXYNUCLEOSIDES; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MODELS, BIOLOGICAL; RADIOPHARMACEUTICALS; SKIN; SKIN NEOPLASMS;

EID: 57149108284     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.053215     Document Type: Article

References (32)

1. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
2. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143-156.
3. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
4. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
5. 18F]3′-Deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653-659.
6. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104-10112.
7. 18F-fluorothymidine PET. J Nucl Med. 2005;46:114-120.
8. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371-380.
9. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169-178.
10. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958.
11. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274-282.
12. 18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
13. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007;34:1003-1011.
14. Hume SP, Myers R. Dedicated small animal scanners: a new tool for drug development? Curr Pharm Des. 2002;8:1497-1511.
15. Pomper MG, Lee JS. Small animal imaging in drug development. Curr Pharm Des. 2005;11:3247-3272.
16. Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67:9337-9345.
17. Lee JS, Orita H, Gabrielson K, et al. FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Pharm Res. 2007;24:1202-1207.
18. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754-1758.
19. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004;45:519-525.
20. 18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412-419.
21. 18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging. 2007;34:1406-1409.
22. Kim JS, Lee JS, Im KC, et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med. 2007;48:1527-1535.
23. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818-1823.
24. Wu HM, Sui G, Lee CC, et al. In vivo quantitation of glucose metabolism in mice using small-animal PETand a microfluidic device. J Nucl Med. 2007;48:837-845.
25. 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J Nucl Med. 2007;48:2037-2045.
26. Kim J, Herrero P, Sharp T, et al. Minimally invasive method of determining blood input function from PET images in rodents. J Nucl Med. 2006;47:330-336.
27. Laforest R, Sharp TL, Engelbach JA, et al. Measurement of input functions in rodents: challenges and solutions. Nucl Med Biol. 2005;32:679-685.
28. Nicolas F, De Sousa G, Thomas P, Placidi M, Lorenzon G, Rahmani R. Comparative metabolism of 3′-azido-3′-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans. Drug Metab Dispos. 1995;23:308-313.
29. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol. 2004;31:829-837.
30. 18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002;4:83-89.
31. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci USA. 1991;88:5819-5823.
32. Barthel H, Aboagye E, Price P. Author reply. Cancer Res. 2003;63:8560.